Duane A Mitchell

Duane A Mitchell, M.D., Ph.D.

Director – UF Clinical And Translational Science Institute; Assistant Vice President For Research – University Of Florida; Associate Dean – UF College Of Medicine

Department: MD-NEUROLOGICAL SURGERY
Business Phone: (352) 273-8700

About Duane A Mitchell

DUANE A. MITCHELL, M.D., PH.D., is the Assistant Vice President for Research at University of Florida and Associate Dean for Translational Science and Clinical Research at the UF College of Medicine. He currently serves as the Director of the UF Clinical and Translational Science Institute and Co-Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy. Dr. Mitchell is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery at University of Florida and the State of Florida Endowed Cancer Research Chair at the UF College of Medicine. Dr. Mitchell graduated from Rutgers College in New Brunswick with a bachelor’s degree in biology before receiving his medical degree (M.D.) and doctorate degree (Ph.D.) in immunology from Duke University in Durham in 2001. Dr. Mitchell received postgraduate training in pathology and neuro-oncology research at Duke University Medical Center prior to joining the faculty as an Assistant Professor. During his tenure at Duke, Dr. Mitchell developed pioneering programs in brain tumor immunotherapy research and held positions as Director of Preclinical Research at the Preston Robert Tisch Brain Tumor Center and Associate Director of the Duke Brain Tumor Immunotherapy Program. He also served as an active member of several institutional regulatory boards governing the conduct of human clinical trials. In 2013, Dr. Mitchell joined the University of Florida faculty and leads a comprehensive brain tumor program focused on clinical and translational research. His addition to the brain tumor program at UF was made possible by the Wells Foundation gift, combined with matching funds from other university sources, totaling over $20 million dedicated to brain tumor treatment and research. He has considerable clinical and translational research experience, holding five FDA-approved investigational new drug applications (INDs) governing the conduct of ten novel immunotherapy clinical trials based on discoveries made in his laboratory. Dr. Mitchell has received many honors and awards including induction into the American Society of Clinical Investigation (ASCI) and a 2016 Top 10 Clinical Research Achievement Award from the Clinical Research Forum in Washington, D.C. for his team’s advancement of a novel therapeutic vaccine for patients with glioblastoma. Dr. Mitchell currently serves as an appointed member of the NCI Board of Scientific Counselors, Chair of the NCI Pediatric Brain Tumor Consortium Immunotherapy Committee and Gubernatorial Appointee to the Florida Center for Brain Tumor Research Scientific Advisory Council. Dr. Mitchell has been invited to serve on numerous scientific advisory boards for private, government, and academic institutions, and to speak on neuro-oncology and cancer immunotherapy in national and international venues. Dr. Mitchell lives in Gainesville, FL with his wife of 20 years, Michelle, and their three sons, Anthony, Brandon, and Austin.

Clinical Profile

Specialties
  • Neurosurgery

Publications

2020
Adult immuno-oncology: using past failures to inform the future.
Neuro-oncology. 22(9):1249-1261 [DOI] 10.1093/neuonc/noaa116. [PMID] 32391559.
2020
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-15129-8. [PMID] 32198351.
2020
RNA-electroporated T cells for cancer immunotherapy.
Oncoimmunology. 9(1) [DOI] 10.1080/2162402X.2020.1792625. [PMID] 33101771.
2020
Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.
Pediatric blood & cancer. [DOI] 10.1002/pbc.28756. [PMID] 33025730.
2020
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(20):5297-5303 [DOI] 10.1158/1078-0432.CCR-20-1082. [PMID] 32719000.
2020
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proceedings of the National Academy of Sciences of the United States of America. 117(2):1129-1138 [DOI] 10.1073/pnas.1910856117. [PMID] 31879345.
2020
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(21):5689-5700 [DOI] 10.1158/1078-0432.CCR-20-1065. [PMID] 32788225.
2020
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.
Cancer research. 80(3):499-509 [DOI] 10.1158/0008-5472.CAN-19-1577. [PMID] 31723000.
2020
Nanoparticles as immunomodulators and translational agents in brain tumors.
Journal of neuro-oncology. [DOI] 10.1007/s11060-020-03559-9. [PMID] 32757093.
2019
IMMU-39. RNA LOADED LIPID-NANOPARTICLES FUNCTION AS CUSTOMIZABLE IMMUNOTHERAPEUTIC VEHICLES AGAINST MALIGNANT GLIOMAS
Neuro-Oncology. 21(6):vi127-vi127 [DOI] 10.1093/neuonc/noz175.531.
2019
IMMU-41. RNA-MODIFIED T CELLS AS PROFESSIONAL ANTIGEN PRESENTING CELLS
Neuro-Oncology. 21(6):vi127-vi128 [DOI] 10.1093/neuonc/noz175.533.
2019
IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS
Neuro-Oncology. 21(6):vi129-vi129 [DOI] 10.1093/neuonc/noz175.539.
2019
IMMUNOLOGIC TARGETING OF DIPG WITH H3K27M ENCODING RNA-NANOPARTICLES: IMMU-07.
Neuro-Oncology. 21
2019
Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy
Science Advances.
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology. 21(6):730-741 [DOI] 10.1093/neuonc/noz015. [PMID] 30668768.
2019
Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy
Cancer Research. 79(13) [DOI] 10.1158/1538-7445.AM2019-4075.
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy. 27(4):837-849 [DOI] 10.1016/j.ymthe.2018.10.007. [PMID] 30448196.
2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Journal for immunotherapy of cancer. 7(1) [DOI] 10.1186/s40425-019-0809-4. [PMID] 31753028.
2019
Sarcosine promotes trafficking of dendritic cells to draining lymph nodes and improves efficacy of a vaccine strategy for the treatment of brain tumors via CX3CL1
. 131(1)
2019
The role of CMV in glioblastoma and implications for immunotherapeutic strategies.
Oncoimmunology. 8(1) [DOI] 10.1080/2162402X.2018.1514921. [PMID] 30546954.
2019
TMIC-08. IDENTIFICATION OF TUMOR SPECIFIC LYMPHOCYTES IN A MURINE GLIOMA MODEL
Neuro-Oncology. 21(6):vi248-vi248 [DOI] 10.1093/neuonc/noz175.1042.
2019
TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
Neuro-Oncology. 21(6):vi253-vi254 [DOI] 10.1093/neuonc/noz175.1063.
2019
TMIC-49. ABROGATING CD70 EXPRESSION IN GBM RESULTS IN A REDUCED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
Neuro-Oncology. 21(6):vi258-vi258 [DOI] 10.1093/neuonc/noz175.1082.
2019
TMIC-50. 3D QUANTIFICATION OF DYNAMIC CYTOKINE GRADIENTS PRODUCED BY PRIMARY TUMOR MODELS
Neuro-Oncology. 21(6):vi258-vi259 [DOI] 10.1093/neuonc/noz175.1084.
2019
TMOD-07. IN SITU MICROSCOPY OF DRUG AND IMMUNE CELL INTERACTIONS AGAINST BIOFABRICATED TUMOR MODELS
Neuro-Oncology. 21(6):vi263-vi264 [DOI] 10.1093/neuonc/noz175.1106.
2019
UNLOCKING CANCER IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS WITH TRANSCRIPTOME LOADED NANOPARTICLES: IMMU-08
Neuro-Oncology. 21
2019
IMMU-32. RNA-NANOPARTICLE VACCINES MEDIATE T CELL TRAFFICKING NECESSARY FOR BBB PASSAGE AND ANTI-GLIOMA IMMUNE RESPONSE
Neuro-Oncology. 21(6):vi125-vi126 [DOI] 10.1093/neuonc/noz175.524.
2019
IMMU-27. IMMUNE CHECKPOINT BLOCKADE OF EX VIVO EXPANDED T CELLS FOR USE IN ADOPTIVE CELLULAR THERAPY (ACT) FOR GLIOBLASTOMA
Neuro-Oncology. 21(6):vi124-vi125 [DOI] 10.1093/neuonc/noz175.517.
2019
Quantitative characterization of 3D bioprinted structural elements under cell generated forces.
Nature communications. 10(1) [DOI] 10.1038/s41467-019-10919-1. [PMID] 31292444.
2019
IMMU-25. MAGNETIC PARTICLE IMAGING FOR NON-INVASIVE TRACKING OF ADOPTIVE CELL TRANSFER IN CANCER IMMUNOTHERAPY
Neuro-Oncology. 21(6):vi124-vi124 [DOI] 10.1093/neuonc/noz175.518.
2019
3D in vitro system for immuno-oncology: Real-time imaging of drug delivery, tumoroids, and immune cell activity
. 79(13) [DOI] 10.1158/1538-7445.AM2019-35.
2019
IMMU-26. RADIATION AND TEMOZOLOMIDE UP-REGULATES CD70 EXPRESSION AND ENHANCES CAR T-CELL RECOGNITION IN GBM
Neuro-Oncology. 21(6):vi124-vi124 [DOI] 10.1093/neuonc/noz175.519.
2019
Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis
Cancer Research. 79(13) [DOI] 10.1158/1538-7445.AM2019-1194.
2019
ATIM-13. MULTIMODAL IMMUNOTHERAPY WITH IO-VAC® FOR PATIENTS WITH GBM: A SINGLE INSTITUTION EXPERIENCE
Neuro-Oncology. 21(6):vi4-vi4 [DOI] 10.1093/neuonc/noz175.013.
2019
ATIM-34. SINGLE-CELL RNA SEQUENCING REVEALS DYNAMIC IMMUNE RESPONSE CHANGES IN GLIOBLASTOMA PATIENT WITH DURABLE COMPLETE RESPONSE TO CMV PP65-LAMP RNA-PULSED DENDRITIC VACCINES
Neuro-Oncology. 21(6):vi9-vi9 [DOI] 10.1093/neuonc/noz175.033.
2019
BSTM-03. INCREASING ANTI-TUMOR T CELL ACTIVATION, VELOCITY, AND MIGRATION TO BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM AND PROGENITOR CELLS
Neuro-Oncology. 21(2):ii67-ii68 [DOI] 10.1093/neuonc/noz036.021.
2019
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.
Stem cells (Dayton, Ohio). 37(2):166-175 [DOI] 10.1002/stem.2933. [PMID] 30353618.
2019
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nature communications. 10(1) [DOI] 10.1038/s41467-019-11869-4. [PMID] 31488817.
2019
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
ACS nano. 13(12):13884-13898 [DOI] 10.1021/acsnano.9b05037. [PMID] 31730332.
2019
Chemotaxis of Spatially Patterned T cell Populations near 3D Printed Tumors
.
2019
EXTH-15. INCREASING THE TRAFFICKING OF DENDRITIC CELLS VIA CXC CHEMOKINE SIGNALING PATHWAY LEADS TO IMPROVED ANTI-TUMOR EFFICACY OF DENDRITIC CELL VACCINES
Neuro-Oncology. 21(6)
2019
IMMU-24. A COMPREHENSIVE IN SILICO APPROACH TO DISCOVERING TUMOR REJECTION ANTIGENS IN MALIGNANT BRAIN TUMORS
Neuro-Oncology. 21(6):vi124-vi124 [DOI] 10.1093/neuonc/noz175.517.
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology. 12(1) [DOI] 10.1186/s13045-019-0756-z. [PMID] 31311607.
2019
IMMU-13. MECHANISMS OF IMMUNOLOGICAL ESCAPE DURING ADOPTIVE CELLULAR THERAPY IN HIGH GRADE GLIOMA
Neuro-Oncology. 21(6):vi121-vi122 [DOI] 10.1093/neuonc/noz175.507.
2019
IMMU-07. CELLULAR IMMUNOTHERAPY TO OVERCOME TEMOZOLOMIDE INDUCED T CELL EXHAUSTION IN GLIOBLASTOMA
Neuro-Oncology. 21(6):vi120-vi120 [DOI] 10.1093/neuonc/noz175.501.
2019
IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA
Neuro-Oncology. 21(6):vi122-vi122 [DOI] 10.1093/neuonc/noz175.509.
2019
Highlights of the inaugural ten–the launch of Neuro-Oncology Advances
Neuro-Oncology Advances. 1(1) [DOI] 10.1093/noajnl/vdz016.
2019
IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA
Neuro-Oncology. 21(6):vi119-vi120 [DOI] 10.1093/neuonc/noz175.499.
2018
Immunotherapy for Brain Tumors.
Current treatment options in oncology. 19(11) [DOI] 10.1007/s11864-018-0576-3. [PMID] 30311004.
2018
PDCT-08. TRACKING THE T CELL REPERTOIRE AFTER ADOPTIVE CELL THERAPY IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA
Neuro-Oncology. 20(6):vi202-vi202 [DOI] 10.1093/neuonc/noy148.840.
2018
Immunotherapy for brain tumors
Current Treatment Options in Oncology. 19(11)
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
The EMBO journal. 37(23) [DOI] 10.15252/embj.201798772. [PMID] 30322894.
2018
Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.
Nature communications. 9(1) [DOI] 10.1038/s41467-018-06182-5. [PMID] 30333482.
2018
MBRS-02. PERSONALIZED IMMUNOTHERAPY WITH TRANSLATABLE RNA NANOPARTICLES TARGETING MEDULLOBLASTOMA
Neuro-Oncology. 20(2):i128-i129 [DOI] 10.1093/neuonc/noy059.449.
2018
MBRS-63. CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME TREATMENT RESISTANCE TO PD-1 IN MEDULLOBLASTOMA
Neuro-Oncology. 20(2):i141-i142 [DOI] 10.1093/neuonc/noy059.507.
2018
mRNA-nanoparticles to enhance and track dendritic cell migration
Journal of Clinical Oncology. 36(5)
2018
PDTM-18. ACTIVATION OF TUMOR-REACTIVE T CELLS AGAINST BRAIN STEM GLIOMA USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology. 20(6):vi207-vi208 [DOI] 10.1093/neuonc/noy148.861.
2018
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY
Neuro-Oncology. 20(6)
2018
STEM-09. CANCER STEM CELL IMMUNOEDITING
Neuro-Oncology. 20(6)
2018
Temozolomide for immunomodulation in the treatment of glioblastoma.
Neuro-oncology. 20(12):1566-1572 [DOI] 10.1093/neuonc/noy072. [PMID] 29733389.
2018
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Frontiers in molecular neuroscience. 11 [DOI] 10.3389/fnmol.2018.00082. [PMID] 29643764.
2018
THE IMPACT OF BRAIN TUMORS ON HEMATOPOIETIC STEM CELL-DERIVED T CELLS: IMMU-24
Neuro-Oncology. 20
2018
TMIC-12. TUMOR-HOMING RNA-NANOPARTICLES REPROGRAM IMMUNE CELLS IN THE BRAIN TUMOR MICROENVIRONMENT
Neuro-Oncology. 20(6):vi258-vi259 [DOI] 10.1093/neuonc/noy148.1073.
2018
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY
Neuro-Oncology. 20(6)
2018
Total tumor RNA pulsed dendritic cells plus adoptive transfer of ex-vivo enriched autologous T-lymphocytes in the treatment of children with primary brain tumors
Neuroimmunology and Neuroinflammation. 5(10) [DOI] 10.20517/2347-8659.2018.44.
2018
IMMU-66. A NOVEL METABOLITE TO INCREASE EFFICACY OF CELLULAR IMMUNOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology. 20(6):vi136-vi136 [DOI] 10.1093/neuonc/noy148.569.
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Nano letters. 18(10):6195-6206 [DOI] 10.1021/acs.nanolett.8b02179. [PMID] 30259750.
2018
IMMU-64. A DECADE OF RESEARCH TARGETING IMMUNOSUPPRESSIVE IDO1 IN GLIOBLASTOMA: NEARING THE FINISH LINE OR JUST BEGINNING THE MARATHON?
Neuro-Oncology. 20(suppl_6):vi136-vi136 [DOI] 10.1093/neuonc/noy148.567.
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma
The EMBO journal. 37(23)
2018
IMMU-67. PERSONALIZED TUMOR MRNA LOADED LIPID NANOPARTICLES PRIME THE SYSTEMIC AND INTRATUMORAL GBM MILIEU FOR RESPONSE TO IMMUNOTHERAPY
Neuro-Oncology. 20(6):vi136-vi137
2018
IMMU-56. CXCR1/2 MODIFIED CARs CO-OPT RADIATION-INDUCED IL-8 FOR ENHANCED CHEMOTAXIS OF THE CAR T CELLS AND MAXIMAL ANTI-TUMOR EFFICACY
Neuro-Oncology. 20(6):vi134-vi134 [DOI] 10.1093/neuonc/noy148.560.
2018
2173 RNA-nanoparticles to enhance and track dendritic cell migration
Journal of Clinical and Translational Science. 2(S1):26-26 [DOI] 10.1017/cts.2018.117.
2018
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
International journal of molecular sciences. 19(10) [DOI] 10.3390/ijms19102890. [PMID] 30249040.
2018
CD70, a novel target of CAR T-cell therapy for gliomas.
Neuro-oncology. 20(1):55-65 [DOI] 10.1093/neuonc/nox116. [PMID] 28651374.
2018
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 24(16):3955-3966 [DOI] 10.1158/1078-0432.CCR-17-3061. [PMID] 29712687.
2018
DDIS-06. AAV TOOLKIT ENABLING PRECISION COMBINATORIAL VIROTHERAPY FOR GLIOBLASTOMA
Neuro-Oncology. 20(6):vi70-vi70 [DOI] 10.1093/neuonc/noy148.284.
2018
Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
Cancer research. 78(1):256-264 [DOI] 10.1158/0008-5472.CAN-17-0469. [PMID] 29093005.
2018
DRES-13. VEGF BLOCKADE ENHANCES T REGULATORY CELL FUNCTION BY DYSREGULATING GLUTAMATE TRANSPORT IN GBM
Neuro-Oncology. 20(6):vi78-vi78 [DOI] 10.1093/neuonc/noy148.320.
2018
EXTH-36. BIFUNCTIONAL RNA NANOPARTICLES INDUCE ANTITUMOR IMMUNE RESPONSES AND ALLOW MRI-BASED DETECTION OF DENDRITIC CELL MIGRATION AS A BIOMARKER OF ANTITUMOR IMMUNE RESPONSE
Neuro-Oncology. 20(6):vi92-vi93 [DOI] 10.1093/neuonc/noy148.381.
2018
IMMU-04. RNA-ENGINEERED T CELLS AS A BIOLOGICAL CARRIER TO DELIVER MACROMOLECULES TO INTRACRANIAL TUMORS
Neuro-Oncology. 20(2):i99-i99 [DOI] 10.1093/neuonc/noy059.320.
2018
Analysis of immunobiologic markers in primary and recurrent glioblastoma
Journal of Neuro-Oncology. 137(2):249-257 [DOI] 10.1007/s11060-017-2732-1. [PMID] 29302887.
2018
IMMU-15. HIGH-RESOLUTION ANALYSIS OF THE T-CELL RECEPTOR REPERTOIRE AFTER ADOPTIVE CELLULAR THERAPY IN PEDIATRIC PATIENTS WITH CENTRAL PNETs (Re-MATCH TRIAL)
Neuro-Oncology. 20(2):i101-i102 [DOI] 10.1093/neuonc/noy059.331.
2018
IMMU-17. HEMATOPOIETIC STEM CELL-DERIVED DENDRITIC CELLS REPROGRAM THE BRAIN TUMOR MICROENVIRONMENT
Neuro-Oncology. 20(2):i102-i102 [DOI] 10.1093/neuonc/noy059.333.
2018
IMMU-20. HEMATOPOIETIC STEM CELLS POTENTIATE EFFICACY OF ADOPTIVE CELL THERAPY AGAINST BRAIN STEM GLIOMA
Neuro-Oncology. 20(2):i102-i103 [DOI] 10.1093/neuonc/noy059.336.
2018
IMMU-27. Re-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) + DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC + ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETs (r-PNET)
Neuro-Oncology. 20(2):i104-i104 [DOI] 10.1093/neuonc/noy059.343.
2018
IMMU-32. RETARGETING IMMUNOEDITED GLIOMA ESCAPE VARIANTS WITH ADOPTIVE CELLULAR THERAPY
Neuro-Oncology. 20(6):vi128-vi128 [DOI] 10.1093/neuonc/noy148.535.
2018
IMMU-43. RNA-MODIFIED T CELLS AS A NON-INVASIVE AND EFFICACIOUS STRATEGY TO DELIVER THERAPEUTIC MACROMOLECULES LOCALLY TO INTRACRANIAL TUMORS
Neuro-Oncology. 20(6):vi130-vi131 [DOI] 10.1093/neuonc/noy148.543.
2018
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
Neuro-Oncology. 20(6)
2018
IMMU-45. DOSE MODULATION OF TEMOZOLOMIDE HAVE DISTINCT EFFECTS ON HOST RESPONSE TO PD-1 BLOCKADE
Neuro-Oncology. 20(6)
2018
IMMU-09. Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a Pediatric Brain Tumor Consortium study (PBTC045)
Neuro-Oncology. 20(2):i100-i100 [DOI] 10.1093/neuonc/noy059.325.
2017
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.
Journal of immunology research. 2017 [DOI] 10.1155/2017/3145742. [PMID] 28265580.
2017
METB-02. A SENSITIVE METABOLIC SIGNATURE TO PREDICT IMMUNE RESPONSE AFTER IMMUNOTHERAPY FOR BRAIN TUMORS
Neuro-Oncology. 19(6):vi128-vi128 [DOI] 10.1093/neuonc/nox168.527.
2017
Overcoming resistance to immune checkpoint blockade with RNA-loaded nanoparticles
Journal of Clinical Oncology. 35(7)
2017
PDCT-12. TRACKING T-CELL IMMUNE RECONSTITUTION AFTER ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PNETS USING DEEP T-CELL RECEPTOR (TCR) REPERTOIRE SEQUENCING
Neuro-Oncology. 19(6)
2017
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Human Vaccines and Immunotherapeutics. 13(6):1208-1209 [DOI] 10.1080/21645515.2017.1332137. [PMID] 28633007.
2017
Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11)
Cancer Immunology Immunotherapy. 66(12):1589-1595 [DOI] 10.1007/s00262-017-2051-6. [PMID] 28825123.
2017
STEM-09. TREATMENT-RESISTANT SLOW-CYCLING CELLS SUPPORT METABOLIC HETEROGENEITY AND ADAPTABILITY IN GLIOBLASTOMA
Neuro-Oncology. 19(6):vi227-vi228
2017
The Effects of New or Worsened Postoperative Neurological Deficits on Survival of Patients With Glioblastoma
Journal of Neurosurgery. 127(1):123-131 [DOI] 10.3171/2016.7.JNS16396.
2017
The Clinical and Financial Impact of a Pediatric Surgical Neuro-Oncology Clinical Trial
Journal of Neuro-Oncology. 132(1):83-87 [DOI] 10.1007/s11060-016-2338-z.
2017
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Seminars in immunopathology. 39(2):225-239 [DOI] 10.1007/s00281-016-0616-7. [PMID] 28138787.
2017
TMIC-12. REPROGRAMMING THE BRAIN TUMOR MICROENVIRONMENT WITH HEMATOPOIETIC STEM AND PROGENITOR CELLS
Neuro-Oncology. 19(6):vi245-vi245 [DOI] 10.1093/neuonc/nox168.1002.
2017
TMIC-26. IMMUNOMODULATION WITH TEMOZOLOMIDE TO IMPROVE EFFICACY OF IMMUNE CHECKPOINT INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology. 19(6):vi248-vi249 [DOI] 10.1093/neuonc/nox168.1015.
2017
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology. 6(10) [DOI] 10.1080/2162402X.2017.1290036. [PMID] 29123947.
2017
Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
International journal of cancer. 141(7):1434-1444 [DOI] 10.1002/ijc.30830. [PMID] 28612394.
2017
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(8):1898-1909 [DOI] 10.1158/1078-0432.CCR-16-2057. [PMID] 28411277.
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology. 6(1) [DOI] 10.1080/2162402X.2016.1256527. [PMID] 28197373.
2017
Immunotherapy for Pediatric Brain Tumors.
Brain sciences. 7(10) [DOI] 10.3390/brainsci7100137. [PMID] 29065490.
2017
IMMU-57. STRATEGY TO ENHANCE DC MIGRATION FOR INCREASED EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Neuro-Oncology. 19(6):vi125-vi125 [DOI] 10.1093/neuonc/nox168.515.
2017
IMMU-63. OVERCOMING GLIOBLASTOMA RESISTANCE TO IMMUNE CHECKPOINT BLOCKADE VIA RNA-LOADED NANOPARTICLES
Neuro-Oncology. 19(6):vi126-vi127 [DOI] 10.1093/neuonc/nox168.520.
2017
IMMU-65. Lin-CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME RESISTANCE TO PD-1 BLOCKADE
Neuro-Oncology. 19(6):vi127-vi127 [DOI] 10.1093/neuonc/nox168.522.
2017
2422: Magnetic nanoparticles facilitate tracking of dendritic cells for treatment of malignant brain tumors
Journal of Clinical and Translational Science. 1(1):9-9 [DOI] 10.1017/cts.2017.48.
2017
A phase I trial of pomalidomide for children with recurrent, progressive/refractory central nervous system (CNS) tumors: A Pediatric Brain Tumor Consortium (PBTC) study.
Journal of Clinical Oncology. 35(15)
2017
Adoptive Immunotherapy Against Brain Tumors
. 323-335 [DOI] 10.1016/B978-0-12-802420-1.00013-2.
2017
CD70 as a critical mediator of tumor progression and immunosuppression in gliomas
Journal of Clinical Oncology. 35(7)
2017
DIPG-23. PHASE I STUDY OF ADOPTIVE CELLULAR THERAPY (X-ALT) PLUS TOTAL TUMOR RNA-DENDRITIC CELL VACCINE (TTRNA-DC) + HEMATOPOIETIC STEM CELLS (HSC) DURING RECOVERY FROM IRRADIATION(RT) WITH (GROUP A) OR WITHOUT (GROUP B) DOSE-INTENSIFIED TEMOZOLOMIDE (DI-TMZ) IN PATIENT (PTS) WITH NEWLY DIAGNOSED DIFFUSE BRAIN STEM GLIOMAS (DIPG) (BRAVO TRIAL)
Neuro-Oncology. 19(4):iv9-iv9 [DOI] 10.1093/neuonc/nox083.038.
2017
IMMU-11. AN ANALYSIS OF IMMUNOPHENOTYPE, INCLUDING PD-L1 AND PD1 EXPRESSION, IN PEDIATRIC CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
Neuro-Oncology. 19(4)
2017
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.
Frontiers in immunology. 8 [DOI] 10.3389/fimmu.2017.01451. [PMID] 29163521.
2017
IMMU-14. REMODELING IMMUNITY AGAINST MEDULLOBLASTOMA VIA RNA LOADED NANOPARTICLES
Neuro-Oncology. 19(4) [DOI] 10.1093/neuonc/nox083.124.
2017
IMMU-22. ADOPTIVE CELL THERAPY AGAINST DIPG USING DEVELOPMENTALLY REGULATED ANTIGENS
Neuro-Oncology. 19(4):iv32-iv32 [DOI] 10.1093/neuonc/nox083.133.
2017
IMMU-25. ENHANCED T CELLS TUMOR RECOGNITION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Neuro-Oncology. 19(6):vi117-vi118 [DOI] 10.1093/neuonc/nox168.483.
2017
IMMU-25. ENHANCED T CELLS TUMOR RECOGNITION USING DENDRITIC CELLS PULSED WITH CHIMERIC RNAs ENCODING FULL-LENGTH LAMP-1 FUSION CONSTRUCTS
Neuro-Oncology. 19(6):vi117-vi118 [DOI] 10.1093/neuonc/nox168.483.
2017
IMMU-30. TCR Vb CLONAL EXPANSION PREDICTS RESPONSE TO ADOPTIVE IMMUNOTHERAPY AGAINST MEDULLOBLASTOMA
Neuro-Oncology. 19(6):vi119-vi119 [DOI] 10.1093/neuonc/nox168.488.
2017
IMMU-31. IN VIVO CELLULAR TRACKING WITH 13C LABELING OF ADOPTIVELY TRANSFERRED T CELLS FOR THE TREATMENT OF BRAIN TUMORS
Neuro-Oncology. 19(6):vi119-vi119 [DOI] 10.1093/neuonc/nox168.489.
2017
IMMU-14. REMODELING IMMUNITY AGAINST MEDULLOBLASTOMA VIA RNA LOADED NANOPARTICLES
Neuro-Oncology. 19(4):iv30-iv30 [DOI] 10.1093/neuonc/nox083.124.
2016
IMST-55. LYMPH NODE AND URINE METABOLOMICS: A NON-INVASIVE STRATEGY TO PREDICT EFFICACY OF DENDRITIC CELL VACCINE IMMUNOTHERAPY
Neuro-Oncology. 18(6)
2016
Prioritization schema for immunotherapy clinical trials in glioblastoma.
Oncoimmunology. 5(6) [DOI] 10.1080/2162402X.2016.1145332. [PMID] 27471611.
2016
PDCT-15. Re-MATCH: A PHASE 2 MULTI-INSTITUTIONAL CLINICAL TRIAL OF ADOPTIVE CELLULAR THERAPY FOLLOWING MYELOABLATIVE OR NON-MYELOABLATIVE CHEMOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Neuro-Oncology. 18(6):vi149-vi149 [DOI] 10.1093/neuonc/now212.619.
2016
Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses
Critical Reviews In Oncology/Hematology. 107:100-110 [DOI] 10.1016/j.critrevonc.2016.09.002.
2016
MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade.
Neuro-oncology. 18(5):601-2 [DOI] 10.1093/neuonc/now003. [PMID] 26980424.
2016
Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups.
Oncoimmunology. 5(11) [DOI] 10.1080/2162402X.2016.1144002. [PMID] 27999733.
2016
IMST-47. IDENTIFICATION AND EXPANSION OF GLIOMA-SPECIFIC T CELLS USING TCR Vβ EXPRESSION
Neuro-Oncology. 18(6)
2016
CMV-targeted Dendritic Cell Vaccines Increase Survival for Randomized Patients with Glioblastoma in Successive Trials
Journal of Neurosurgery. 124(4):A1181-A11182
2016
IMST-16. TRANSLATABLE RNA NANOPARTICLES SUPPLANT DENDRITIC CELL VACCINES IN CELLULAR IMMUNOTHERAPY
Neuro-Oncology. 18(6)
2016
Gene-modified dendritic cell vaccines for cancer.
Cytotherapy. 18(11):1446-1455 [DOI] 10.1016/j.jcyt.2016.09.009. [PMID] 27745604.
2016
Disruption of KIF3A in patient-derived glioblastoma cells: effects on ciliogenesis, hedgehog sensitivity, and tumorigenesis.
Oncotarget. 7(6):7029-43 [DOI] 10.18632/oncotarget.6854. [PMID] 26760767.
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(3):582-95 [DOI] 10.1158/1078-0432.CCR-15-0713. [PMID] 26405194.
2016
COMBINATION OF VEGF-A AND PD-1 BLOCKADE MAY ENHANCE ANTITUMOR EFFICACY IN GBM
Neuro-Oncology. 18
2016
IMST-27. CD70–A CRITICAL MEDIATOR OF TUMOR PROGRESSION AND IMMUNOSUPPRESSION IN GLIOMAS
Neuro-Oncology. 18(6)
2016
QUANTITATIVE TRACKING OF T-CELL CLONES AFTER ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA USING MASSIVELY PARALLEL RNA SEQUENCING TECHNOLOGY
Neuro-Oncology. 18
2016
Reviewer Lists for Neuro-Oncology
Neuro-Oncology. 18(1):2-4 [DOI] 10.1093/neuonc/nov308.
2016
TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT
Neuro-Oncology. 18(6)
2016
Vaccine-related allergic reaction: case report
. 1589
2016
Tetanus-Diphtheria Recall Responses and Chemokine CCL3 Delivery Enhance Migration and Efficacy of Dendritic Cell Vaccines
Journal Of Neurosurgery. 124(4)
2015
Vaccination strategies for neuro-oncology.
Neuro-oncology. 17 Suppl 7:vii15-vii25 [DOI] 10.1093/neuonc/nov159. [PMID] 26516221.
2015
Tetanus toxoid conditioning enhances migration and efficacy of dendritic cell vaccines in patients with glioblastoma
. 122(6)
2015
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Nature. 519(7543):366-369
2015
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Cancer immunology research. 3(4):320-5 [DOI] 10.1158/2326-6066.CIR-14-0100. [PMID] 25387895.
2015
RNA NANOPARTICLE VACCINES FACILITATE AND SUSTAIN ADOPTIVE CELLULAR THERAPY TARGETING PEDIATRIC INTRACRANIAL MALIGNANCIES: YOUNG INVESTIGATOR AWARD WINNER# 4012
Pediatric Blood & Cancer. 62
2015
Rna Nanoparticle Vaccines Facilitate and Sustain Adoptive Cellular Therapy Targeting Pediatric Intracranial Malignancies
Pediatric Blood & Cancer. 62(2)
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology. 4(3) [PMID] 25949916.
View on: PubMed
2015
METB-02USING MAGNETIC RESONANCE SPECTROSCOPY TO TRACK DENDRITIC CELLS FOR VACCINE IMMUNOTHERAPY
Neuro-Oncology. 17(5):v135-v135 [DOI] 10.1093/neuonc/nov221.02.
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
Cancer Immunology Immunotherapy. 64(4):419-427
2015
IMPS-42 CD70—A KEY DRIVER OF CHEMOKINE-MEDIATED IMMUNE SUPPRESSION AND INDICATOR OF NEGATIVE PROGNOSIS FOR GLIOBLASTOMA
Neuro-Oncology. 17(5)
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII. 64(4):419-27 [DOI] 10.1007/s00262-014-1651-7. [PMID] 25555571.
2015
IMPS-25DIFFERENTIAL TUMOR MICROENVIRONMENTS AND RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN MOLECULAR SUBTYPES OF MURINE MEDULLOBLASTOMA
Neuro-Oncology. 17(5):v118-v118 [DOI] 10.1093/neuonc/nov217.24.
2015
IM-15ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY IS SIGNIFICANTLY INCREASED BY HEMATOPOIETIC STEM CELLS
Neuro-Oncology. 17(3):iii18-iii18 [DOI] 10.1093/neuonc/nov061.69.
2015
IM-14IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES USING DEVELOPMENTALLY REGULATED ANTIGENS
Neuro-Oncology. 17(3):iii17-iii18 [DOI] 10.1093/neuonc/nov061.68.
2015
IM-13MOLECULAR ENGINEERING OF AMPLIFIED TUMOR RNA-PULSED DENDRITIC CELLS IN ADOPTIVE CELLULAR THERAPY TARGETING MEDULLOBLASTOMA AND GLIOBLASTOMA
Neuro-Oncology. 17(3):iii17-iii17 [DOI] 10.1093/neuonc/nov061.67.
2015
IM-12 RNA NANOPARTICLE VACCINES RE-PROGRAM HOST IMMUNITY IN FAVOR OF ENHANCED EFFECTOR RESPONSES AGAINST INTRACRANIAL MALIGNANCIES
Neuro-Oncology. 17(3)
2015
IM-12 RNA NANOPARTICLE VACCINES RE-PROGRAM HOST IMMUNITY IN FAVOR OF ENHANCED EFFECTOR RESPONSES AGAINST INTRACRANIAL MALIGNANCIES
Neuro-Oncology. 17(3)
2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Neuro-Oncology. 17(7):912-914
2015
Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma.
Journal of neuro-oncology. 125(1):65-74 [DOI] 10.1007/s11060-015-1890-2. [PMID] 26311248.
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer. 3 [DOI] 10.1186/s40425-015-0058-0. [PMID] 25901285.
2015
IMPS-36RNA NANOPARTICLE VACCINES RE-PROGRAM HOST-IMMUNITY AGAINST GLIOBLASTOMA INDUCING THERAPEUTIC ANTI-TUMOR ACTIVITY
Neuro-Oncology. 17(5):v121-v121 [DOI] 10.1093/neuonc/nov217.35.
2014
IT-31HARNESSING THE IMMUNOLOGIC CAPACITY OF THE LIVER AGAINST GLIOBLASTOMA MULTIFORME
Neuro-Oncology. 16(5):v116-v116 [DOI] 10.1093/neuonc/nou258.29.
2014
ROBUST INDUCTION OF TYPE-1 CD8+ T-CELL RESPONSES IN WHO GRADE II LOW-GRADE GLIOMA PATIENTS RECEIVING PEPTIDE-BASED VACCINES IN COMBINATION WITH POLY-ICLC
Neuro-Oncology. 16(3):iii39-iii39 [DOI] 10.1093/neuonc/nou208.62.
2014
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells
Clinical Cancer Research. 20(10):2684-2694 [DOI] 10.1158/1078-0432.CCR-13-3268.
2014
Memory Responses Govern Dendritic Cell Migration to Vaccine-Site Draining Lymph Nodes Resulting in Enhanced Anti-Tumor Efficacy
Journal of Surgical Research. 186(2) [DOI] 10.1016/j.jss.2013.11.515.
2014
IT-25DEVELOPMENTALLY REGULATED ANTIGENS FOR IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES
Neuro-Oncology. 16(5):v115-v115 [DOI] 10.1093/neuonc/nou258.23.
2014
IT-35 cGMP MANUFACTURING OF EX VIVO EXPANDED TUMOR-SPECIFIC T CELLS AND AMPLIFIED TUMOR RNA-PULSED DC VACCINES TARGETING GLIOBLASTOMA AND MEDULLOBLASTOMA
Neuro-Oncology. 16(5):v117-v117 [DOI] 10.1093/neuonc/nou258.33.
2014
IT-06PERSONALIZED IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA
Neuro-Oncology. 16(5):v111-v111 [DOI] 10.1093/neuonc/nou258.5.
2014
Immunological targeting of cytomegalovirus for glioblastoma therapy.
Oncoimmunology. 3 [PMID] 25101224.
View on: PubMed
2014
GE-11THE FLORIDA CENTER FOR BRAIN TUMOR RESEARCH (FCBTR): BUILDING INFRASTRUCTURE TO FIND A CURE
Neuro-Oncology. 16(5):v98-v98 [DOI] 10.1093/neuonc/nou256.11.
2014
Differential role for host translation factors in host and viral protein synthesis during human cytomegalovirus infection
Journal Of Virology. 88(3):1473-1483 [DOI] 10.1128/JVI.02321-13. [PMID] 24198422.
2014
IT-10SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA
Neuro-Oncology. 16(5):v111-v111 [DOI] 10.1093/neuonc/nou258.8.
2013
IMMUNOTHERAPY/BIOLOGICAL THERAPIES
Neuro-Oncology. 15(3):iii68-iii74 [DOI] 10.1093/neuonc/not178.
2013
Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
. 1(1)
2013
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Proceedings of the National Academy of Sciences of the United States of America. 110(1):270-5 [DOI] 10.1073/pnas.1219817110. [PMID] 23248284.
2013
Special Issue On Epilepsy
Experimental Neurology. 244:1-3 [DOI] 10.1016/j.expneurol.2013.04.006. [PMID] 23651566.
2013
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one. 8(3) [DOI] 10.1371/journal.pone.0059082. [PMID] 23527092.
2013
Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.
The Journal of clinical investigation. 123(7):3135-45 [DOI] 10.1172/JCI67544. [PMID] 23934126.
2013
IT-017. TARGETING IDH1 MUTATIONS USING PEPTIDE VACCINES IN BRAIN TUMORS
Neuro-Oncology. 15(3)
2013
IT-004. A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY
Neuro-Oncology. 15(3)
2013
IT-004. A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY
Neuro-Oncology. 15(3)
2013
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
Cancer immunology research. 1(3) [DOI] 10.1158/2326-6066.CIR-13-0049. [PMID] 24570975.
2013
ENGINEERING RNA NANOPARTICLE VACCINES TO TARGET MALIGNANT PEDIATRIC BRAIN TUMORS: PLATFORM SESSION 413-TRAVEL STIPEND AWARD WINNER
Pediatric Blood & Cancer. 60
2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII. 62(6):983-7 [DOI] 10.1007/s00262-013-1405-y. [PMID] 23591978.
2013
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Future oncology (London, England). 9(7):977-90 [DOI] 10.2217/fon.13.47. [PMID] 23837761.
2013
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
Expert review of vaccines. 12(6):597-615 [DOI] 10.1586/erv.13.41. [PMID] 23750791.
2013
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
Expert review of clinical pharmacology. 6(4):375-86 [DOI] 10.1586/17512433.2013.811806. [PMID] 23927666.
2013
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Cancer immunology, immunotherapy : CII. 62(11):1649-62 [DOI] 10.1007/s00262-013-1464-0. [PMID] 23982483.
2013
0175. A PHASE I/II STUDY OF ADOPTIVE T- CELL THERAPY (ALT) AND DC VACCINATION (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HDC + ASCR) OR NON-MYELOABLATIVE CONDITIONING (NMA) IN PATIENTS (PTS) WITH RECURRENT CENTRAL PNETS (RE-MATCH PROTOCOL)
Neuro-Oncology. 15(1)
2013
0157. NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology. 15(1)
2013
0157. NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS
Neuro-Oncology. 15(1)
2013
0003. PRELIMINARY STUDY Rg3-NANOPARTICLES TREAT GLIOBLASTOMA CELLS
Neuro-Oncology. 15(1)
2012
IT-20. DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION
Neuro-Oncology. 14(6)
2012
IT-26. FEASIBILITY OF AMPLIFIED CD133 (+) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology. 14(6)
2012
IT-27. ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PRIMITIVE NEUROECTODERMAL TUMORS AFTER MYELOABLATIVE AND NON-MYELOABLATIVE CONDITIONING
Neuro-Oncology. 14(6)
2012
IT-20. DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION
Neuro-Oncology. 14(6)
2012
RNA NANOPARTICLE VACCINES TARGETING MEDULLOBLASTOMA:(POSTER 698)
Pediatric Blood & Cancer. 58(7)
2012
Monoclonal antibody therapy for malignant glioma.
Advances in experimental medicine and biology. 746:121-41 [DOI] 10.1007/978-1-4614-3146-6_10. [PMID] 22639164.
2012
IT-09. EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS
Neuro-Oncology. 14(6)
2012
TM-14. DEVELOPMENT OF IMMUNOCOMPETENT SYNGENEIC MODELS OF MEDULLOBLASTOMA FOR EVALUATION OF IMMUNOTHERAPY
Neuro-Oncology. 14(6)
2012
IR-13. MYELOABLATIVE TEMOZOLOMIDE INCREASES ANTIGEN-SPECIFIC CD8+ T-CELL VACCINE RESPONSES AND IS REQUIRED FOR EFFICACIOUS IMMUNOTHERAPY AGAINST INTRACEREBRAL TUMORS
Neuro-Oncology. 14(6)
2012
IR-09. DEVELOPING RNA NANOPARTICLE VACCINES TARGETING PEDIATRIC AND ADULT BRAIN TUMORS
Neuro-Oncology. 14(6)
2012
IR-08. ASSESSMENT OF INTRATUMORAL TREGS AND CLINICAL OUTCOMES IN PRIMARY AND RECURRENT GLIOBLASTOMA
Neuro-Oncology. 14(6)
2012
Immunotherapy of brain tumors.
Handbook of clinical neurology. 104:309-30 [DOI] 10.1016/B978-0-444-52138-5.00020-7. [PMID] 22230450.
2012
ET-49. ROLE OF HEMATOPOIETIC STEM CELLS IN ENHANCING THE ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY
Neuro-Oncology. 14(6)
2012
Chasing cancer with chimeric antigen receptor therapy.
Immunotherapy. 4(4):365-7 [DOI] 10.2217/imt.12.16. [PMID] 22512629.
2012
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
PloS one. 7(2) [DOI] 10.1371/journal.pone.0031046. [PMID] 22383993.
2012
IR-15. ENHANCEMENT OF DENDRITIC CELL MIGRATION TO VACCINE-SITE DRAINING LYMPH NODES AS A MEANS TO GENERATE POTENT ANTI-TUMOR IMMUNE RESPONSES
Neuro-Oncology. 14(6)
2011
Reply to MS Lesniak
Journal of Clinical Oncology. 29(22):3105-3106
2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood. 118(11):3003-12 [DOI] 10.1182/blood-2011-02-334565. [PMID] 21768296.
2011
Is cytomegalovirus a therapeutic target in glioblastoma?
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(14):4619-21 [DOI] 10.1158/1078-0432.CCR-11-0992. [PMID] 21632859.
2011
Immunotherapy for glioblastoma: The Devil Is in the Details Reply
Journal of Clinical Oncology. 29(22):3105-3106 [DOI] 10.1200/JCO.2011.35.0256.
2011
IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY DIAGNOSED MEDULLOBLASTOMA
Neuro-Oncology. 13
2011
IMMUNOLOGIC PROFILE OF PATIENTS WITH NEWLY DIAGNOSED MEDULLOBLASTOMA
Neuro-Oncology. 13
2011
Temozolamide and Radiation Therapy Does Not Cause EGFRvIII Loss
Journal Of Neurosurgery. 115(2)
2011
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro-oncology. 13(3):324-33 [DOI] 10.1093/neuonc/noq157. [PMID] 21149254.
2011
Direct2Experts Collaboration Direct2Experts: a pilot national network to demonstrate interoperability among research-networking platforms
Journal of the American Medical Informatics Association. 18(1):i157-i160
2011
Direct2Experts Collaboration Direct2Experts: a pilot national network to demonstrate interoperability among research-networking platforms
Journal of the American Medical Informatics Association. 18(1):i157-i160
2011
Cellular Immunotherapy for Malignant Brain Tumors
.
2011
ADOPTIVE CELLULAR THERAPY DURING RECOVERY FROM TREATMENT-INDUCED LYMPHOPENIA IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
Neuro-Oncology. 13
2011
A promising cancer vaccine
Future Oncology. 7(3):331-334 [DOI] 10.2217/fon.11.17.
2011
IM-23. CYTOMEGALOVIRUS-SPECIFIC IMMUNE DEFICITS IN PATIENTS WITH GBM
Neuro-Oncology. 13(3)
2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4722-9 [DOI] 10.1200/JCO.2010.28.6963. [PMID] 20921459.
2010
Interleukin-2 receptor α (IL-2R α/CD25)-specific antibodies eliminate regulatory T-cells (TRegs) and enhance tumor-specific immune responses
. 70(8) [DOI] 10.1158/1538-7445.AM10-5611.
2010
Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
Cancer immunology, immunotherapy : CII. 59(2):183-93 [DOI] 10.1007/s00262-009-0757-9. [PMID] 19756596.
2009
Toward effective immunotherapy for the treatment of malignant brain tumors.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 6(3):527-38 [DOI] 10.1016/j.nurt.2009.04.003. [PMID] 19560742.
2009
Proteomic and immunologic analyses of brain tumor exosomes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 23(5):1541-57 [DOI] 10.1096/fj.08-122184. [PMID] 19109410.
2009
INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM
Neuro-Oncology. 11(2)
2009
Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM
Journal of Clinical Oncology. 27(15)
2009
EGFRvIII-targeted vaccination therapy of malignant glioma.
Brain pathology (Zurich, Switzerland). 19(4):713-23 [DOI] 10.1111/j.1750-3639.2009.00318.x. [PMID] 19744042.
2009
CELLULAR IMMUNOTHERAPY TRIALS TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN GLIOBLASTOMA
Neuro-Oncology. 11(5)
2009
CELLULAR IMMUNOTHERAPY TRIALS TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN GLIOBLASTOMA
Neuro-Oncology. 11(5)
2009
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Molecular cancer therapeutics. 8(10):2773-9 [DOI] 10.1158/1535-7163.MCT-09-0124. [PMID] 19825799.
2009
236. RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma
. 17 [DOI] 10.1016/S1525-0016(16)38594-X.
2009
Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM
Journal of Clinical Oncology. 27(15S)
2008
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Seminars in immunology. 20(5):267-75 [DOI] 10.1016/j.smim.2008.04.001. [PMID] 18539480.
2008
THE POSITIVE INFLUENCE OF TEMOZOLOMIDE ON THE HUMORAL AND CELL-MEDIATED (DTH) RESPONSES TO EGFRVIII-TARGETED VACCINE (CDX-110) IN PATIENTS WITH GBM
Neuro-Oncology. 10(5)
2008
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
Neuro-oncology. 10(1):10-8 [PMID] 17951512.
View on: PubMed
2008
Immunotherapy of malignant brain tumors.
Immunological reviews. 222:70-100 [DOI] 10.1111/j.1600-065X.2008.00603.x. [PMID] 18363995.
2008
Selective modification of antigen-specific T cells by RNA electroporation.
Human gene therapy. 19(5):511-21 [DOI] 10.1089/hum.2007.115. [PMID] 18471037.
2008
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Neuro-oncology. 10(1):98-103 [PMID] 18079360.
View on: PubMed
2008
Efficacy and immunologic effects of RNA-pulsed dendritic cell vaccines targeting human cytomegalovirus antigens in patients with glioblastoma
. 68(9)
2008
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
Cancer immunology, immunotherapy : CII. 57(1):115-21 [PMID] 17634939.
View on: PubMed
2008
A phase I/II clinical trial evaluating RNA-loaded dendritic cells targeting human cytomegalovirus in patients with newly-diagnosed GBM
Journal of Neurosurgery. 108(4):A849-A850
2008
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Journal of immunological methods. 339(1):74-81 [DOI] 10.1016/j.jim.2008.08.004. [PMID] 18775433.
2008
Humoral and cell mediated responses to the EGFRvIII-targeted vaccine (CDX-110) are enhanced with continuous temozolomide in patients with GBM
. 68(9)
2008
Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM
Journal of Clinical Oncology. 26(15)
2008
Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
Journal of Clinical Oncology. 26(15)
2007
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
Journal of neuroimmunology. 182(1-2):63-72 [PMID] 17137636.
View on: PubMed
2007
Induction of enhanced immunologic responses during hematopoeitic recovery from temozolomide-induced lymphopenia
Neuro-Oncology. 9(4)
2007
RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma
Neuro-Oncology. 9(4)
2007
Temozolomide as a vaccine adjuvant in GBM
Journal of Clinical Oncology. 25(18)
2007
Temozolomide therapy induces an increase in regulatory T-cells without abbrogating a specific tumor
Neuro-Oncology. 9(4)
2007
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(7):2158-67 [PMID] 17404100.
View on: PubMed
2006
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer research. 66(6):3294-302 [PMID] 16540683.
View on: PubMed
2006
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(24):7306-15 [PMID] 17189402.
View on: PubMed
2006
Radiotherapy with regulatory T-cell depletion is synergistic for treatment of experimental model of malignant glioma
. 104(4):A637-A638
2006
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(14 Pt 1):4294-305 [PMID] 16857805.
View on: PubMed
2005
Immunotherapy for Malignant Glioma
.
2005
Expression profiling of CD4+ and CD8+ T cells in malignant glioma
Clinical Cancer Research. 11(24)
2005
Expression profiling of CD4+ and CD8+ T cells in malignant glioma
Clinical Cancer Research. 11(24)
2004
Cytomegalovirus-specific antigens are effective targets for adoptive immunotherapy in malignant gliomas
Neuro-Oncology. 6(4)
2004
Detection and immunologic recognition of cytomegalovirus antigens expressed within malignant gliomas
Neuro-Oncology. 6(4)
2004
Development and characterization of a novel murine brain tumor model of cytomegalovirus-associateid malignant astrocytoma
Neuro-Oncology. 6(4)
2003
Adoptive immunotherapy for malignant glioma.
Cancer journal (Sudbury, Mass.). 9(3):157-66 [PMID] 12952301.
View on: PubMed
2003
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
Journal of neuro-oncology. 64(1-2):161-76 [PMID] 12952297.
View on: PubMed
2001
Dendritic Cell Therapy
. 1-27
2000
Dendritic cells capture tumor derived antigens in vivo and mediate class I-restricted” cross-priming” of tumor specific cytotoxic T-cells
Journal of Investigative Dermatology. 114(1)
2000
RNA-transfected dendritic cells in cancer immunotherapy
The Journal Of Clinical Investigation. 106(9):1065-1069 [DOI] 10.1172/JCI11405. [PMID] 11067858.
1999
Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides
Journal of Immunology. 162(11):6426-6432 [PMID] 10352256.
View on: PubMed
1998
Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells
European Journal of Immunology. 28(6):1923-1933 [DOI] 10.1002/(SICI)1521-4141(199806)28:06<1923::AID-IMMU1923>3.0.CO;2-9. [PMID] 9645374.
1998
Direct demonstration of” cross-priming”: In situ transfer of tumor antigen to dendritic cells
Journal Of Leukocyte Biology.
1996
I-131 anti-CD45 antibody as a part of a conditioning regimen prior to bone marrow transplantation acute leukemia
Journal of Nuclear Medicine. 37(5)
1994
Molecular biology of Cryptococcus neoformans and therapy of cryptococcosis
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology. 32(1):407-415 [PMID] 7722801.
View on: PubMed
1990
Selection of antihypertensive therapy
American heart journal. 119(6):1446-1448 [DOI] 10.1016/s0002-8703(05)80214-5. [PMID] 2386595.
1989
Dosages for Labetalol
Chest. 96(6) [DOI] 10.1378/chest.96.6.1444-a. [PMID] 2582867.

Grants

Sep 2020 ACTIVE
Optimizing Adoptive Cell Therapy for Glioblastoma Using Novel Noninvasive Magnetic Particle Imaging
Role: Mentor
Funding: AMER BRAIN TUMOR ASSOCIATION
Sep 2020 ACTIVE
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
Role:
Funding: NATL INST OF HLTH NINDS
Jul 2020 ACTIVE
White House Study: Evaluate COVID-19 Detection Technology
Role: Principal Investigator
Funding: ASST SEC FOR PREPAREDNESS AND RESPONSE
Jul 2020 ACTIVE
Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
Role: Mentor
Funding: NATL INST OF HLTH NIDCR
Jul 2020 ACTIVE
RNA-nanoparticle vaccines for pediatric high-grade glioma
Role:
Funding: CURESEARCH FOR CHILDRENS CANCER
Jul 2020 ACTIVE
The STAT3 Inhibitor LLL12B Regulates Immune Activation in Medulloblastoma
Role: Mentor
Funding: Rally Foundation
Jul 2020 ACTIVE
Together Transforming and Translating Discovery to Improve Health
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Jun 2020 ACTIVE
CXCL9 AAV-engineered neutrophils as a novel Trojan Horse cellular therapy to promote T cell chemotaxis in GBM
Role: Mentor
Funding: UF FOU via CIRCLE OF HOPE FOR CANCER RES INC
Jan 2020 ACTIVE
Examination of CNS Uptake
Role: Principal Investigator
Funding: CURIS
Dec 2019 ACTIVE
A vaccine strategy to overcome treatment induced immunosuppression in glioma
Role:
Funding: AMER BRAIN TUMOR ASSOCIATION
Sep 2019 ACTIVE
Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomas
Role:
Funding: NATL INST OF HLTH NINDS
Aug 2019 ACTIVE
Reprogramming Host Immunity in Treatment-Resistant Head and Neck Cancer Using Personalized RNA Nanoparticle Vaccines
Role:
Funding: TRIOLOGICAL SOCIETY
Jul 2019 – Jun 2020
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jul 2019 ACTIVE
Together: Transforming and Translating Discovery to Improve Health
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Jul 2019 ACTIVE
COM CTSI Institutional Support
Role: Principal Investigator
Funding: FL CLINICAL PRACTICE ASSO
Jul 2019 ACTIVE
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Role:
Funding: Rally Foundation
Jul 2019 ACTIVE
OoR Matching Support for CTSI
Role: Principal Investigator
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Sep 2018 ACTIVE
A 3D Tissue Map of the Human Lymphatic System
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Sep 2018 ACTIVE
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
Role: Project Manager
Funding: NATL INST OF HLTH NINDS
Jul 2018 – Jul 2019
Engineering a Clinically Accessible Biomarker for Glioblastoma Immunotherapy
Role: Project Manager
Funding: CIRCLE OF HOPE FOR CANCER RES INC
May 2018 ACTIVE
Engineering RNA-nanoparticles to enhance dendritic cell mediated treatment of glioblastoma
Role: Mentor
Funding: NATL INST OF HLTH NCI
Feb 2018 – Jan 2019
Engineering a clinically accessible biomarker for glioblastoma immunotherapy
Role: Principal Investigator
Funding: UF FOU via CIRCLE OF HOPE FOR CANCER RES INC
Nov 2017 – Nov 2020
Selective Expansion of Neoantigen-Specific T Cells Targeting Medulloblastoma
Role: Principal Investigator
Funding: THE V FOU FOR CANCER RESEARCH
Sep 2017 – Sep 2020
RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
Role:
Funding: US ARMY MED RES ACQUISITION
Sep 2017 ACTIVE
Immunologic Targeting of Developmentally-Regulated Antigens for the Treatment of High-Risk Medulloblastoma
Role: Mentor
Funding: NATL INST OF HLTH NCI
Jul 2017 ACTIVE
Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials Network
Role: Project Manager
Funding: NATL INST OF HLTH NHLBI
Jul 2017 – Jul 2020
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy During Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Role: Principal Investigator
Funding: THE LYLA NSOULI FOU CHILDRENS BRAIN CANC
Jul 2017 ACTIVE
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I)
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR via NATL PEDIATRIC CANCER FOU
Jun 2017 – Jun 2020
Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Role: Principal Investigator
Funding: ACCELERATE BRAIN CANCER CURE
Apr 2017 ACTIVE
OoR CTSI Institutional Matching Support
Role: Principal Investigator
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Dec 2016 ACTIVE
Leveraging Temozolomide to Improve Treatment Efficacy of Immune Checkpoint Blockade in Glioblastoma
Role: Mentor
Funding: NATL INST OF HLTH NINDS
Sep 2016 ACTIVE
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
Role: Mentor
Funding: NATL INST OF HLTH NCI
Apr 2016 ACTIVE
A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs
Role: Principal Investigator
Funding: ST JUDE CHILDRENS RESEARCH HOSPITAL via NATL INST OF HLTH NCI
Apr 2016 – Mar 2019
A Phase I Trial of Pomalidomide for children with recurrent, progressive or refractory CNS tumors
Role: Principal Investigator
Funding: ST JUDE CHILDRENS RESEARCH HOSPITAL via NATL INST OF HLTH
Jan 2016 – Jan 2020
Immunologic targeting of molecular subtypes of medullobl
Role: Principal Investigator
Funding: HYUNDAI HOPE ON WHEELS
Sep 2015 – Aug 2016
Establish comparative immunogenicity of LAMP modified pp
Role: Principal Investigator
Funding: IMMUNOMIC THERAPEUTICS INC
Aug 2015 ACTIVE
CTSI Institutional Support
Role: Principal Investigator
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Aug 2015 ACTIVE
Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jun 2015 ACTIVE
Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade Gliomas
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
May 2015 – May 2017
Therapeutic Targeting of immune metabolism
Role: Project Manager
Funding: UF DIV OF SPONSORED RESEARCH
Apr 2015 ACTIVE
Clinical and Translational Science Institute (CTSI)
Role: Principal Investigator
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Apr 2015 – Mar 2020
Pediatric Brain Tumor Consortium
Role: Principal Investigator
Funding: CHILDRENS RESEARCH INSTITUTE via NATL INST OF HLTH NCI
Dec 2014 – May 2016
PCF – The Sunshine Project
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR via PEDIATRIC CANCER RESEARCH FOU
Jan 2014 ACTIVE
DENDRITIC CELL (DC) AND TUMOR-SPECIFIC CYTOTOXIC T CELL (CTL) GENERATION PROTOCOL FROM HEALTHY VOLUNTEERS AND PATIENTS WITH MALIGNANT BRIAN TUMORS
Role: Principal Investigator
Funding: UF FOU
Jul 2013 ACTIVE
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
Role: Project Manager
Funding: FL DEPT OF HLTH
Jul 2013 – Jun 2020
Endowed Research Chair
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jul 2013 – Dec 2019
Re-MATCH: Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive Cell Therapy During Recovery from Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Jul 2013 – Jun 2016
R01 transfer
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS

Patents

Published January 2018
Hematopoietic Stem Cells in Combinatorial Therapy with Immune Checkpoint Inhibitors Against Cancer
#US-2018-0214544-A1

Teaching Profile

Courses Taught
2018-2019
EGN4912 Engineering Directed Independent Research
2018
GMS7979 Advanced Research
2018
GMS7980 Research for Doctoral Dissertation
2018
BME7980 Research for Doctoral Dissertation
2016
GMS6140 Principles of Immunology
2014
GMS6029 Brain Journal Club
2013
GMS7794 Neuroscience Seminar

Contact Details

Phones:
Business:
(352) 273-8700